Skip to main content
Top
Published in: Diabetologia 1/2006

01-01-2006 | Research Letter

PPARGC1A mRNA levels of in vitro differentiated human skeletal muscle cells are negatively associated with the plasma oleate concentrations of the donors

Authors: H. Staiger, N. Stefan, F. Machicao, A. Fritsche, H.-U. Häring

Published in: Diabetologia | Issue 1/2006

Login to get access

Excerpt

To the Editor: Peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α (PGC-1α) is a metabolically relevant transcriptional coactivator protein. Through PPARs and nuclear respiratory factor-1, it enhances adaptive thermogenesis, oxidative phosphorylation, mitochondrial biogenesis and β-oxidation in adipose tissue and skeletal muscle [1]. Obese, insulin-resistant and type 2 diabetic states reveal low muscle mitochondrial oxidative capacity, reduced expression of respiratory chain components, and decreased expression of the gene encoding PGC-1α (PPARGC1A) [2, 3]. We have recently shown that PPARGC1A expression in in vitro differentiated human skeletal muscle cells (myotubes) is induced by common unsaturated plasma NEFAs, such as palmitoleate, oleate and linoleate, but is not influenced by common saturated NEFAs, such as myristate, palmitate and stearate [4]. In the present study, we investigated (1) whether the basal expression of PPARGC1A and the gene encoding its close homologue, PGC-1β (PPARGC1B) in myotubes derived from metabolically characterised white donors display marked individual variations, and, if so, (2) whether these variations are linked to in vivo metabolic features of the donors, such as adiposity, insulin resistance, total NEFA concentration, or concentration of individual plasma NEFAs. …
Literature
1.
go back to reference Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr Rev 24:78–90PubMedCrossRef Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr Rev 24:78–90PubMedCrossRef
2.
go back to reference Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273PubMedCrossRef Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273PubMedCrossRef
3.
go back to reference Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466–8471PubMedCrossRef Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466–8471PubMedCrossRef
4.
go back to reference Staiger H, Staiger K, Haas C, Weisser M, Machicao F, Häring HU (2005) Fatty acid-induced differential regulation of the genes encoding peroxisome proliferator-activated receptor-γ coactivator-1α and -1β in human skeletal muscle cells that have been differentiated in vitro. Diabetologia (online first, DOI: 10.1007/s00125-005-1895-z) Staiger H, Staiger K, Haas C, Weisser M, Machicao F, Häring HU (2005) Fatty acid-induced differential regulation of the genes encoding peroxisome proliferator-activated receptor-γ coactivator-1α and -1β in human skeletal muscle cells that have been differentiated in vitro. Diabetologia (online first, DOI: 10.1007/s00125-005-1895-z)
5.
go back to reference Tschritter O, Fritsche A, Thamer C et al (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243PubMedCrossRef Tschritter O, Fritsche A, Thamer C et al (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243PubMedCrossRef
6.
go back to reference Stefan N, Wahl HG, Fritsche A, Häring H, Stumvoll M (2001) Effect of the pattern of elevated free fatty acids on insulin sensitivity and insulin secretion in healthy humans. Horm Metab Res 33:432–438PubMedCrossRef Stefan N, Wahl HG, Fritsche A, Häring H, Stumvoll M (2001) Effect of the pattern of elevated free fatty acids on insulin sensitivity and insulin secretion in healthy humans. Horm Metab Res 33:432–438PubMedCrossRef
7.
go back to reference Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20:1868–1876PubMedCrossRef Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20:1868–1876PubMedCrossRef
8.
go back to reference Oberkofler H, Linnemayr V, Weitgasser R et al (2004) Complex haplotypes of the PGC-1α gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 53:1385–1393PubMedCrossRef Oberkofler H, Linnemayr V, Weitgasser R et al (2004) Complex haplotypes of the PGC-1α gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 53:1385–1393PubMedCrossRef
Metadata
Title
PPARGC1A mRNA levels of in vitro differentiated human skeletal muscle cells are negatively associated with the plasma oleate concentrations of the donors
Authors
H. Staiger
N. Stefan
F. Machicao
A. Fritsche
H.-U. Häring
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0061-y

Other articles of this Issue 1/2006

Diabetologia 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine